# Clinical Research Assistant — Executive Feature Guide

**One AI platform spanning the entire clinical-research lifecycle — from the first literature search to regulatory-grade trial execution to the published manuscript and patient results letter.**

<div class="meta-strip">
<b>Audience:</b> research directors · sponsors · institutional leadership · procurement &nbsp;•&nbsp;
<b>Companion:</b> hands-on <i>walkthrough guides</i> (for researchers &amp; investigators) demonstrate each tool step-by-step.
</div>

---

## The problem it solves

A single trial moves through **six phases over months or years** — evidence synthesis, trial design, regulatory start-up, execution, analysis & reporting, dissemination. Historically each phase needs its own software (reference managers, EDC, randomisation, statistics, submission tooling, medical writing). Teams lose more time **re-typing the same study into each silo** than doing the science, and **every handoff between tools is an audit and compliance risk**.

## What CRA is

One platform organised around *how research actually flows*, not around what each piece of software does. Two complementary halves sit on a **single data spine**:

- **🔬 Research & Evidence** — find, appraise, synthesise, and publish evidence.
- **🏥 Trial Management & Execution** — design, run, capture, and report a regulated trial.

The same PICO that scopes a meta-analysis **seeds** the statistical analysis plan. The same subject randomised in the eCRF flows automatically into the CDISC submission, the Clinical Study Report, and the patient results letter — **with no re-typing and a continuous audit trail**.

> **The differentiator in one line:** most tools *manage* the workflow; CRA *does the methodological work* — composing search queries, running meta-analyses in a sandboxed compute environment, deriving CDISC datasets, drafting ICH-E3 reports — while enforcing anti-fabrication guardrails at every step.

---

## Lifecycle coverage at a glance

<div class="chart">
<div class="bar-row"><span class="bar-label">01 · Evidence synthesis</span><span class="bar"><span class="fill" style="width:75%">9 tools</span></span></div>
<div class="bar-row"><span class="bar-label">02 · Trial design</span><span class="bar"><span class="fill" style="width:17%">2</span></span></div>
<div class="bar-row"><span class="bar-label">03 · Start-up</span><span class="bar"><span class="fill" style="width:17%">2</span></span></div>
<div class="bar-row"><span class="bar-label">04 · Execution</span><span class="bar"><span class="fill" style="width:100%">12 tools</span></span></div>
<div class="bar-row"><span class="bar-label">05 · Analysis &amp; reporting</span><span class="bar"><span class="fill" style="width:58%">7 tools</span></span></div>
<div class="bar-row"><span class="bar-label">06 · Infrastructure</span><span class="bar"><span class="fill" style="width:75%">9 tools</span></span></div>
</div>

| Phase | What leadership gets | Headline deliverables |
|---|---|---|
| **01 Evidence synthesis** | A defensible evidence base for protocols, grants, HTA & guideline submissions | Search strategy · SR protocol · screening · meta-analysis · GRADE/PRISMA |
| **02 Trial design** | A powered, peer-review-ready trial design | Sample-size calculation · ICH-E9 Statistical Analysis Plan |
| **03 Start-up** | Faster regulatory & ethics approval | Trial-registration drafts (CT.gov / EU CTIS) · IRB packet + consent form |
| **04 Execution** | Regulatory-grade data capture at scale | eCRF/EDC · ePRO · randomisation · safety · drug accountability · lab feeds |
| **05 Analysis & reporting** | Submission- and publication-ready outputs | CDISC SDTM→ADaM→TLF · CSR · manuscript · lay summary |
| **06 Infrastructure** | Governance, oversight & cost control | RBAC · audit · portfolio & budget dashboards · multi-tenant deployment |

---

## 🔬 Research & Evidence — highlights

| Capability | Benefit to the institution |
|---|---|
| **Multi-source search strategy** | Reproducible, registration-ready Boolean queries across PubMed, Europe PMC, Embase, Cochrane, Scopus, Web of Science in one pass. |
| **Systematic-review screening** | Blinded dual review + AI-assist + auto PRISMA flow — collapses the single biggest SR time-sink. |
| **Meta-analysis (pairwise, network, IPD)** | Pooled effects, heterogeneity, funnel/Egger, and gold-standard individual-patient analyses — all run in a sandbox, never invented. |
| **GRADE + PRISMA 2020** | Journal- and guideline-grade certainty ratings and reporting checklists, computed not asserted. |
| **Living-review watches** | Scheduled re-search with materiality alerts and committee-quorum voting — keeps guidelines current automatically. |
| **Manuscript & lay-summary drafters** | IMRaD manuscripts with reviewer-response loops, and reading-level-graded patient summaries. |

## 🏥 Trial Management & Execution — highlights

| Capability | Benefit to the institution |
|---|---|
| **AI-assisted eCRF design** | CRFs drafted from a protocol in minutes, with CDASH naming, edit-checks, and immutable versioned publishing. |
| **EDC capture + queries** | Hard checks block bad data; soft checks auto-raise queries; every change is audited (old→new, who, when). |
| **Randomisation / IRT** | Blinded allocation, multiple algorithms, PI-only emergency unblinding — fully auditable. |
| **Safety (AE/SAE)** | ICH-E2A auto-classification, 24-hour reporting timer, FDA 3500A drafting. |
| **Operations suite** | Recruitment/CONSORT funnels · visit scheduling & reminders · drug accountability · EHR & lab-feed ingestion. |
| **Multi-site coordination** | Per-site KPI rollups for enrolment, query backlog, safety, and operations across an entire programme. |

---

## Compliance & governance — built in, not bolted on

| Standard | What CRA enforces |
|---|---|
| **21 CFR Part 11 / ALCOA+** | Append-only audit trails, e-signature with password re-authentication, immutable published forms. |
| **ICH E6 (GCP)** | Role-based access, delegation logs with PI countersignature, training-record tracking, separation-of-duties at user setup. |
| **ICH E9 / E9(R1)** | SAPs structured around the estimands framework; statistics run in a controlled compute environment. |
| **ICH E3 · E2A** | Standardised Clinical Study Reports and adverse-event safety workflows. |
| **CDISC (SDTM / ADaM / Define-XML / ODM)** | Submission-ready datasets and form definitions exported in regulator-expected formats. |
| **21 CFR §50.25 · PRISMA · GRADE · CONSORT** | Consent-form element checks, and reporting standards baked into evidence outputs. |

**Data governance:** PHI (clinical) and research data live in **separate stores**; the platform is **multi-tenant** (many institutions, isolated), with a **formal IQ/OQ/PQ validation pack** available for inspection readiness.

---

## Why CRA is different

- **Single data spine** — one study, entered once, flows across all six phases. No re-typing, no reconciliation.
- **Anti-fabrication by design** — the system refuses to invent effect sizes, PMIDs, statistics, or registry IDs; numbers trace to a source or a sandboxed computation.
- **Audit-by-default** — every clinical write is captured; reports are regulator-formatted.
- **Cost transparency** — per-study and per-organisation usage and spend dashboards.
- **One platform, not a suite** — replaces a stack of disconnected tools and the integration burden between them.

<div class="numbers">
<div class="num"><b>40+</b><span>integrated capabilities</span></div>
<div class="num"><b>6</b><span>lifecycle phases, one platform</span></div>
<div class="num"><b>1,500+</b><span>automated tests</span></div>
<div class="num"><b>15+</b><span>regulatory standards enforced</span></div>
</div>

---

## In short

The Clinical Research Assistant lets an institution run the **complete research lifecycle on one governed platform** — accelerating evidence synthesis and trial start-up, hardening data capture and safety to inspection standard, and producing submission- and publication-ready outputs — while a continuous audit trail and built-in compliance reduce both cycle time and regulatory risk. Researchers get a tireless co-investigator; leadership gets oversight, defensibility, and a lower total cost of ownership.
